Neuromotor markers of risk for schizophrenia.
OBJECTIVE
To evaluate the possibility of using neuromotor deviation (NMD) as an individual-orientated, early life marker for increased risk for schizophrenia.


METHODS
Previous findings based on systematic examination of NMD are summarised concerning schizophrenia patients and individuals at heightened genetic risk for schizophrenia.


RESULTS
Significantly increased rates of NMD are found in patients with schizophrenia, both after and long before disease onset. Neuromotor deviation can be efficiently studied at all ages from infancy to adulthood, and is typically not in itself stigmatising. Neuromotor deviation may represent an unstable characteristic of individuals from infancy to middle-to-late childhood, possibly attaining greater stability thereafter. Neuromotor deviation may also be more stable over time in the high-risk offspring of parents with schizophrenia than in other children. Neuromotor deviation in childhood predicts subsequent serious mental disturbance in genetic high-risk children. The efficiency of NMD for predicting schizophrenia in unselected samples is unknown, as is the optimal age(s) for assessing NMD to predict schizophrenia in high-risk and normal-risk groups. Neuromotor deviation is also found in the well relatives of schizophrenia patients, individuals developing a broad range of mental and physical disorders, and mentally normal individuals in the general population.


CONCLUSIONS
Neuromotor deviation should definitely be included in batteries of methods for identifying individuals with notably heightened risk of schizophrenia. However, NMD is not pathognomonic for schizophrenia, and the investigation of NMD during childhood and adolescence must thus be used judiciously in order to avoid possible stigmatisation. Further research should be done concerning the specific forms and developmental timing of NMD as related to schizophrenia.
McNeil
T F
TF
Department of Community Medicine, University Hospital, Malmö, Sweden. Thomas.McNeil@smi.mas.lu.se
Cantor-Graae
E
E
D000328:Adult; D002648:Child; D020022:Genetic Predisposition to Disease; D006801:Humans; D009468:Neuromuscular Diseases / Q000235:genetics* / Q000517:prevention & control; D009483:Neuropsychological Tests; D011596:Psychomotor Disorders / Q000235:genetics* / Q000517:prevention & control; D012307:Risk Factors; D012559:Schizophrenia / Q000235:genetics* / Q000517:prevention & control